Sapablursen was granted Fast Track designation and orphan drug designation in 2024 by the U.S. Food and Drug Administration (FDA).

Sapablursen, an antisense oligonucleotide, targets the transmembrane protease serine 6 (TMPRSS6) mRNA. TMPRSS6 is a key negative regulator of the expression of the iron-regulatory hormone hepcidin.

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Sapablursen is currently in a phase 2 trial for polycythemia vera (PV), a rare blood condition characterized by the overproduction of red blood cells. As part of the licensing deal with Ono, Ionis ...

Ionis is continuing to study sapablursen in polycythemia vera, a type of chronic leukemia characterized by dysregulated iron metabolism. A phase 2 study in that indication kicked off in 2021 and ...

"We are pleased to entrust sapablursen to Ono, whose unique capabilities will help maximize its value by ensuring broad access for people living with PV," said Brett P. Monia, Ph.D., chief ...

Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. See how Matt Maley is positioning for post-Fed volatility and momentum—live this Sunday ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global ...